EDWARDS LIFESCIENCES CORP (EW) Stock Price & Overview
NYSE:EW • US28176E1082
Current stock price
The current stock price of EW is 81.81 USD. Today EW is down by -3.31%. In the past month the price increased by 7.03%. In the past year, price increased by 18.07%.
EW Key Statistics
- Market Cap
- 47.515B
- P/E
- 31.96
- Fwd P/E
- 27.15
- EPS (TTM)
- 2.56
- Dividend Yield
- N/A
EW Stock Performance
EW Stock Chart
EW Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to EW. When comparing the yearly performance of all stocks, EW turns out to be only a medium performer in the overall market: it outperformed 68.5% of all stocks.
EW Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to EW. EW scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
EW Earnings
On February 10, 2026 EW reported an EPS of 0.58 and a revenue of 1.57B. The company missed EPS expectations (-8.84% surprise) and missed revenue expectations (-1.47% surprise).
EW Forecast & Estimates
43 analysts have analysed EW and the average price target is 97.45 USD. This implies a price increase of 19.12% is expected in the next year compared to the current price of 81.81.
For the next year, analysts expect an EPS growth of 17.7% and a revenue growth 10.66% for EW
EW Groups
Sector & Classification
EW Financial Highlights
Over the last trailing twelve months EW reported a non-GAAP Earnings per Share(EPS) of 2.56. The EPS decreased by -2.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.69% | ||
| ROA | 7.84% | ||
| ROE | 10.38% | ||
| Debt/Equity | 0.06 |
EW Ownership
EW Latest News, Press Relases and Analysis
EW Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 18.81 | 187.722B | ||
| ISRG | INTUITIVE SURGICAL INC | 46.2 | 167.678B | ||
| SYK | STRYKER CORP | 22.27 | 128.879B | ||
| BSX | BOSTON SCIENTIFIC CORP | 19.77 | 102.581B | ||
| IDXX | IDEXX LABORATORIES INC | 38.71 | 45.688B | ||
| BDX | BECTON DICKINSON AND CO | 11.69 | 45.376B | ||
| RMD | RESMED INC | 18.8 | 33.629B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.69 | 32.253B | ||
| DXCM | DEXCOM INC | 25.27 | 24.723B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.99 | 18.235B | ||
| HOLX | HOLOGIC INC | 15.3 | 16.77B | ||
| PODD | INSULET CORP | 34 | 15.477B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EW
Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Company Info
IPO: 2000-03-27
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA 92614 US
CEO: Michael A. Mussallem
Employees: 16000
Phone: 13026587581
EDWARDS LIFESCIENCES CORP / EW FAQ
What does EW do?
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
What is the current price of EW stock?
The current stock price of EW is 81.81 USD. The price decreased by -3.31% in the last trading session.
Does EDWARDS LIFESCIENCES CORP pay dividends?
EW does not pay a dividend.
How is the ChartMill rating for EDWARDS LIFESCIENCES CORP?
EW has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the valuation of EDWARDS LIFESCIENCES CORP (EW) based on its PE ratio?
The PE ratio for EDWARDS LIFESCIENCES CORP (EW) is 31.96. This is based on the reported non-GAAP earnings per share of 2.56 and the current share price of 81.81 USD.
What is the Short Interest ratio of EDWARDS LIFESCIENCES CORP (EW) stock?
The outstanding short interest for EDWARDS LIFESCIENCES CORP (EW) is 1.38% of its float.